06 Sep 2017
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows
Shield Therapeutics Plc (STX:LON) | 1.3 0 0.0% | Mkt Cap: 10.4m
- Published:
06 Sep 2017 -
Author:
Roger Franklin | Graham Doyle -
Pages:
2